Aripiprazole Tablet
Product Images NDC 50090-4665

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-4665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over time in days from randomization, comparing Aripiprazole and Placebo groups. The number of subjects at risk is displayed below the x-axis at various time points up to 182 days.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier plot showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole (solid line) and placebo (dashed line). The chart includes the number of subjects at risk for each group at various time points up to 364 days.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A plot depicting fold change and 90% confidence intervals for Dehydro-Aripiprazole pharmacokinetics (AUC and Cmax) in the presence of several inhibitors and inducers, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs such as valproate, lithium, and lorazepam. The x-axis shows change relative to reference (without interacting drug).*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters (DMVDR, AUC, and Cmax) of various drugs and enzymes relative to a reference without interacting drug. The y-axis lists substances like CYP2D6, CYP2C9, CYP2C19, S-warfarin, R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis shows change relative to reference from 0.0 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals in AUC and Cmax metrics. The chart compares variables including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with fold change values relative to reference indicated on the x-axis.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot chart illustrating the fold change and 90% confidence interval for dehydro-aripiprazole pharmacokinetic parameters (AUC and Cmax) relative to reference groups. The chart compares effects based on CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the effect of various inhibitors and inducers on Aripiprazole exposure. The chart compares AUC and Cmax fold changes relative to a reference without interacting drugs, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of Aripiprazole, depicting its molecular framework with chlorine-substituted aromatic rings, piperazine, and quinolinone moieties connected via an ether linkage.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over time between Aripiprazole (solid blue line) and placebo (dashed red line) groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Below the x-axis, the number of subjects at risk for each group is listed at intervals.*

FDA Label Image

Label Image (Lbl500904665)

Aripiprazole 5 mg oral tablets packaged by A-S Medication Solutions, Libertyville, IL 60048. The label includes the NDC 50090-4665-0, specifies each tablet contains Aripiprazole USP 5 mg, and the package contains 30 tablets. Storage instructions note to store at 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.